Bio-Rad partners with Seegene

By staff writers

July 1, 2021 -- Bio-Rad Laboratories announced a partnership with South Korean molecular diagnostics company Seegene to develop and commercialize new diagnostic products for diagnosing infectious diseases.

Seegene will provide diagnostic tests for use on Bio-Rad's CFX96 Dx polymerase chain reaction (PCR) detection system, pending clinical development and clearance from the U.S. Food and Drug Administration, Bio-Rad said.

Seegene's assays offer multiplex real-time PCR detection and differentiation, with high sensitivity and specificity of up to seven targets in a single reaction, according to Bio-Rad.

Bio-Rad's sales rise in Q4, full fiscal year
Bio-Rad Laboratories announced a jump in sales for its fourth quarter and full fiscal year due to increased demand for COVID-19 assays.
Top companies earn 80% of revenue in IVD market
Most of the revenue in the IVD market is generated by fewer than 20 companies, according to a recent report by IVD market research firm Kalorama Information,...
Market for IVD to reach $83.3B
The COVID-19 pandemic is having a dramatic impact on the market, according to Bruce Carlson, Kalorama Information publisher. An upcoming report from Kalorama...
Bio-Rad's Q2 revenue drops
Bio-Rad Laboratories reported that the COVID-19 pandemic negatively impacted its revenue for the second quarter as well as for the first half of the year.

Copyright © 2021

Last Updated ls 7/1/2021 2:08:47 PM